A Randomized, Double Blind Placebo Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of AMG 570 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2017
At a glance
- Drugs MEDI 0700 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 25 Jul 2017 Planned number of patients changed from 40 to 48.
- 25 Jul 2017 Planned End Date changed from 1 Aug 2017 to 26 Oct 2017.
- 25 Jul 2017 Planned primary completion date changed from 1 Aug 2017 to 26 Oct 2017.